{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T07:57:51Z","timestamp":1780559871876,"version":"3.54.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.radonc.2015.01.008","type":"journal-article","created":{"date-parts":[[2015,1,22]],"date-time":"2015-01-22T13:30:43Z","timestamp":1421933443000},"page":"206-211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["A new method to estimate doses to the normal tissues after past extended and involved field radiotherapy for Hodgkin lymphoma"],"prefix":"10.1016","volume":"114","author":[{"given":"Maja V.","family":"Maraldo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lundemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan R.","family":"Vogelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Specht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2015.01.008_b0005","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2010.29.8018","article-title":"Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin\u2019s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial","volume":"28","author":"Eich","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2015.01.008_b0010","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2015.01.008_b0015","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/0014-2964(79)90138-5","article-title":"Long-term results of the E.O.R.T.C. randomized study of irradiation and vinblastine in clinical stages I and II of Hodgkin\u2019s disease","volume":"15","author":"Tubiana","year":"1979","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2015.01.008_b0020","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1200\/JCO.2003.03.023","volume":"21","author":"Engert","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2015.01.008_b0025","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1056\/NEJMoa064601","article-title":"Chemotherapy plus involved-field radiation in early-stage Hodgkin\u2019s disease","volume":"357","author":"Ferme","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2015.01.008_b0030","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.ijrobp.2012.08.041","article-title":"Involved node radiation therapy: an effective alternative in early-stage Hodgkin lymphoma","volume":"85","author":"Maraldo","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.01.008_b0035","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood-2006-07-034405","article-title":"Late cardiotoxicity after treatment for Hodgkin lymphoma","volume":"109","author":"Aleman","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.radonc.2015.01.008_b0040","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood-2002-02-0634","article-title":"Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors","volume":"100","author":"Ng","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.radonc.2015.01.008_b0045","doi-asserted-by":"crossref","unstructured":"De Bruin ML, Sparidans J, van\u2019t Veer MB, et al. Breast cancer risk in female survivors of Hodgkin\u2019s lymphoma: lower risk after smaller radiation volumes. J Clin Oncol 2009;27:4239\u201346.","DOI":"10.1200\/JCO.2008.19.9174"},{"key":"10.1016\/j.radonc.2015.01.008_b0050","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1001\/jama.1993.03510160067031","article-title":"Factors affecting late mortality from heart disease after treatment of Hodgkin\u2019s disease","volume":"270","author":"Hancock","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.radonc.2015.01.008_b0055","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ijrobp.2009.10.058","article-title":"Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer","volume":"79","author":"Feng","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.01.008_b0060","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.3109\/0284186X.2013.813636","article-title":"The effect on esophagus after different radiotherapy techniques for early stage Hodgkin\u2019s lymphoma","volume":"52","author":"Jorgensen","year":"2013","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2015.01.008_b0065","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1093\/annonc\/mdt156","article-title":"Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma","volume":"24","author":"Maraldo","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2015.01.008_b0070","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ijrobp.2013.06.004","article-title":"Doses to carotid arteries after modern radiation therapy for Hodgkin lymphoma: is stroke still a late effect of treatment?","volume":"87","author":"Maraldo","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.01.008_b0075","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.radonc.2013.09.027","article-title":"Doses to head and neck normal tissues for early stage Hodgkin lymphoma after involved node radiotherapy","volume":"110","author":"Maraldo","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2015.01.008_b0080","first-page":"1860","article-title":"Report of the committee on Hodgkin\u2019s disease staging classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2015.01.008_b0085","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1182\/blood.V106.11.814.814","article-title":"Comparison of three radiation dose levels after EBVP regimen in favorable supradiaphragmatic clinical stages (CS) I\u2013II Hodgkin\u2019s lymphoma (HL): preliminary results of the EORTC-GELA H9-F trial","volume":"106","author":"Eghbali","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.radonc.2015.01.008_b0090","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1182\/blood.V106.11.813.813","article-title":"Four ABVD and involved-field radiotherapy in unfavorable supradiaphragmatic clinical stages (CS) I\u2013II Hodgkin\u2019s lymphoma (HL): preliminary results of the EORTC-GELA H9-U trial","volume":"106","author":"Ferme","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.radonc.2015.01.008_b0095","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/1748-717X-8-164","article-title":"Clinical implications in the use of the PBC algorithm versus the AAA by comparison of different NTCP models\/parameters","volume":"8","author":"Bufacchi","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2015.01.008_b0100","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1118\/1.1568978","article-title":"CERR: a computational environment for radiotherapy research","volume":"30","author":"Deasy","year":"2003","journal-title":"Med Phys"},{"key":"10.1016\/j.radonc.2015.01.008_b0105","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.ijrobp.2007.05.034","article-title":"Cardiac exposures in breast cancer radiotherapy: 1950s\u20131990s","volume":"69","author":"Taylor","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.01.008_b0110","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.radonc.2008.09.029","article-title":"Cardiac doses from Swedish breast cancer radiotherapy since the 1950s","volume":"90","author":"Taylor","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2015.01.008_b0115","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/jnci\/94.3.182","article-title":"Lung cancer following chemotherapy and radiotherapy for Hodgkin\u2019s disease","volume":"94","author":"Travis","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.radonc.2015.01.008_b0120","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/jama.290.4.465","article-title":"Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease","volume":"290","author":"Travis","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.radonc.2015.01.008_b0125","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1093\/jnci\/95.13.971","article-title":"Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin\u2019s disease","volume":"95","author":"van Leeuwen","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.radonc.2015.01.008_b0130","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1748-717X-2-13","article-title":"A comparison of mantle versus involved-field radiotherapy for Hodgkin\u2019s lymphoma: reduction in normal tissue dose and second cancer risk","volume":"2","author":"Koh","year":"2007","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2015.01.008_b0135","doi-asserted-by":"crossref","first-page":"e557","DOI":"10.1016\/j.ijrobp.2012.06.026","article-title":"Individualized 3D reconstruction of normal tissue dose for patients with long-term follow-up: a step toward understanding dose risk for late toxicity","volume":"84","author":"Ng","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.01.008_b0140","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1748-717X-1-10","article-title":"3-D reconstruction of anterior mantle-field techniques in Hodgkin\u2019s disease survivors: doses to cardiac structures","volume":"1","author":"Vordermark","year":"2006","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2015.01.008_b0145","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814015000341?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814015000341?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T06:40:02Z","timestamp":1598683202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814015000341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0167814015000341"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2015.01.008","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A new method to estimate doses to the normal tissues after past extended and involved field radiotherapy for Hodgkin lymphoma","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2015.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}